



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                        |
|--|---|----|---|--------------------------|------------------------|
| <b>Substitute for form 1449/PTO</b><br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    |   | <b>Complete if Known</b> |                        |
|  |   |    |   | Application Number       | 10/560,385-Conf. #3846 |
|  |   |    |   | Filing Date              | January 12, 2007       |
|  |   |    |   | First Named Inventor     | Michael G. Orchard     |
|  |   |    |   | Art Unit                 | 1614                   |
|  |   |    |   | Examiner Name            | Not Yet Assigned       |
| Sheet  | 1 | of | 3 | Attorney Docket Number   | A0345.0021             |

| U.S. PATENT DOCUMENTS |                          |  |                                |  |   |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|                       |                          | Number-Kind Code <sup>2</sup> (if known) |                                |  |   |
|                       |                          |  |                                |  |   |

| FOREIGN PATENT DOCUMENTS |                          |   |  |                                   |  |   |                |
|--------------------------|--------------------------|---|--|-----------------------------------|--|---|----------------|
| Examiner<br>Initials*    | Cite<br>No. <sup>1</sup> | Foreign Patent Document   |  | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear | T <sup>6</sup> |
|                          |                          | Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) |  |                                   |  |   |                |
|                          | BA                       | EP-0 536 402  |  | 04-14-1993                        | Nippon Shinyaku Company                            |   | ✓              |
|                          | BB                       | EP 0 698 012 (WO-94/26714)  |  | 11-24-1994                        | G.D. Searle & Co et al.                            |   | ✓              |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS |                          |   |                    |
|---------------------------------|--------------------------|---|--------------------|
| Examiner<br>Initials            | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.         | T <sup>2</sup>     |
|                                 | CA                       | GIULIO ALESSANDRI, ET AL., "Angiogenic and Angiostatic Microenvironment in Tumors," <i>Anct Onco.</i> (1997), 36(4), pp. 383-387  |                    |
|                                 | CB                       | ANTHONY LUCCI, ET AL., "Glucosylceramide: a Marker for Multiple-Drug Resistant Cancers," <i>Anticancer Res.</i> (1998), 18(1B), pp. 475-480   |                    |
|                                 | CC                       | PETER DE MAN, ET AL., "Bacterial adherence as a virulence factor in urinary tract infection," <i>APMIS</i> (1990), 98(12), pp. 1053-1060  |                    |
|                                 | CD                       | KM NICHOLSON, ET AL., "Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase," <i>Br. J. Cancer</i> (1999), 81(3), pp. 423-430  |                    |
|                                 | CE                       | GUNNAR C. HANSSON, ET AL., "A novel approach to the study of glycolipid receptors for viruses," <i>FEBS Lett.</i> (1984), 170(1), pp. 15-18   |                    |
|                                 | CF                       | VICTOR JIMENEZ-LUCHO, ET AL., "Cryptococcus neoformans, Candida albicans, and Other Fungi Bind Specifically to the Glycosphingolipid Lactosylceramide (Galβ1-4Glcβ1-1Cer), a Possible Adhesion Receptor for Yeasts," <i>Infect. Immun.</i> (1990), 58(7), pp. 2085-2090 |                    |
|                                 | CG                       | YAAKOV LAVIE, ET AL., "Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells," <i>J. Biol. Chem.</i> (1997) 272(3), pp. 1682-1687            |                    |
|                                 | CH                       | YONG-YU LIU, ET AL., "Uncoupling Ceramide Glycosylation of Transfection of Glucosylceramide Synthase Antisense Reverses Adriamycin Resistance," <i>J. Biol. Chem.</i> (2000), 275(10), pp. 7138-7143  |                    |
|                                 | CI                       | RUIXIANG LI, ET AL., "Cellular Gangliosides Promote Growth Factor-induced Proliferation of Fibroblasts," <i>J. Biol. Chem.</i> (2000), 275(44), pp. 34213-34223   |                    |
|                                 | CJ                       | IVAN Z. ZADOR, ET AL., "A Role for Glycosphingolipid Accumulation in the Renal Hypertrophy of Streptozotocin-induced Diabetes Mellitus," <i>Clin. Invest.</i> (1993), 91(3), pp. 797-903  |                    |
|                                 | CK                       | AKIRA ABE, ET AL., "Reduction of globotriaosylceramide in Fabry disease mice by substrate   |                    |
| Examiner<br>Signature           |                          |   | Date<br>Considered |

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                        |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |                        |
|  |   |    |   | Application Number       | 10/560,385-Conf. #3846 |
|  |   |    |   | Filing Date              | January 12, 2007       |
|  |   |    |   | First Named Inventor     | Michael G. Orchard     |
|  |   |    |   | Art Unit                 | 1614                   |
|  |   |    |   | Examiner Name            | Not Yet Assigned       |
| Sheet  | 2 | of | 3 | Attorney Docket Number   | A0345.0021             |

|     |  |  |  |
|-----|--|--|--|
|     |  | deprivation," J. Clin. Invest. (2000), 105(11), pp. 1563-1571  |  |
| CL  |  | ROBERT MCKALLIP, ET AL., "Tumor Gangliosides Inhibit the Tumor-Specific Immune Response," J. Immuno. (1999), 163(7), pp. 3718-3726   |  |
| CM  |  | MAJLIS SVENSSON, ET AL., "Carbohydrate Receptor Depletion as an Antimicrobial Strategy for Prevention of Urinary Tract Infection," J. Infect. Dis. (2001), suppl. 70-73, p. 183                                |  |
| CN  |  | SUBROTO CHATTERJEE, ET AL., "Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease," J. Lipid. Res. (1996), 37(6), pp. 1334-1344           |  |
| CO  |  | TIMOTHY COX, ET AL., "Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis," Lancet (2000), 355(9214), pp. 1481-1485                            |  |
| CP  |  | N.V. PROKAZOVA, ET AL., "Gangliosides and Atherosclerosis," Lipids (1994), 29(1), pp. 1-5  |  |
| CQ  |  | KAZUKO HANDA, ET AL., "Analysis of Glycolipid-Dependent Cell Adhesion Based on Carbohydrate-Carbohydrate Interaction," Methods Enzymol. (2000), 312, pp. 447-458   |  |
| CR  |  | CLIFFORD A. LINGWOOD, ET AL., "Analysis of Interactions between Glycosphingolipids and Microbial Toxins," Methods Enzymol. (2000), 312, pp. 459-473  |  |
| CS  |  | ABDERRAHIM MERZAK, ET AL., "Gangliosides Modulate Proliferation, Migration, and Invasiveness of Human Brain Tumor Cells In Vitro," Mol. Chem. Neuropathol. (1995), 24(2-3), pp. 121-135                        |  |
| CT  |  | KAI SIMONS ET AL., "Functional rafts in cell membranes," Nature (1997), 387(6633), pp. 569-572   |  |
| CU  |  | PRAVEEN TYLE, "Ionophoretic Devices for Drug Delivery," Pharmaceutical Research (1986), 3(6), p. 318   |  |
| CV  |  | LINDA A. GOODMAN, ET AL., "Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in $\alpha$ -mannosidosis," Proc. Natl. Acad. Sci. USA (1991), 88(24), pp. 11330-11334 |  |
| CW  |  | CHII-SHIARING CHEN, ET AL., "Abnormal transport along the lysosomal pathway in Mucopolipidosis, type IV disease," Proc. Natl. Acad. Sci. USA (1998), 95(11), pp. 6373-6378                                     |  |
| CX  |  | MYLVAGANAM JEYAKUMAR, ET AL., "Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin," Proc. Natl. Acad. Sci. USA (1999), 96(11), pp. 6388-6393    |  |
| CY  |  | Protective Groups in Organic Chemistry, T.W. Greene and P.G.M. Wuts, (Wiley-Interscience, New York, 2nd edition) (1991)  |  |
| CZ  |  | FRANCES M. PLATT, ET AL., "Prevention of Lysosomal Storage in Tay-Sachs Mice Treated with N-Butyldeoxynojirimycin," Science (1997), 276(5311), pp. 428-431   |  |
| CA1 |  | MILTON ALTER, "GM <sub>1</sub> , Ganglioside for Acute Ischemic Stroke," Alter, Ann. NY Acad. Sci. (1998), 845, pp. 391-401  |  |
| CB1 |  | LIN-PING CHOO-SMITH ET AL., "Acceleration of Amyloid Fibril Formation by Specific Binding of A $\beta$ -(1-40) Peptide to Ganglioside-containing Membrane Vesicles," Biol. Chem. (1997), 272, pp. 22987-22990  |  |
| CC1 |  | FOWLER, P.A. ET AL., "Synthesis and activity towards yeast $\alpha$ -glucosidase of 1,5-dideoxy-1,5-imino-L-iditol (1-deoxy-L-idonojirimycin), Carbohydr. Res. (1993), 246, pp. 377-381                        |  |
| CD1 |  | FRED H. GEISLER, "Clinical Trials of Pharmacotherapy for Spinal Cord Injury," NY Acad. Sci. (1998), 845, pp. 374-381   |  |
| CE1 |  | MEMON, R.A. ET AL., "Regulation of Glycosphingolipid Metabolism in Liver during the Acute Phase Response," J. Biol. Chem. (1999), 274(28), pp. 19707-19713   |  |
| CF1 |  | MEMON, R.A., ET AL., "Regulation of sphingolipid and glycosphingolipid metabolism in   |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |   |                          |                        |
|--|---|----|---|--------------------------|------------------------|
| Substitute for form 1449/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |   | <b>Complete if Known</b> |                        |
|  |   |    |   | Application Number       | 10/560,385-Conf. #3846 |
|  |   |    |   | Filing Date              | January 12, 2007       |
|  |   |    |   | First Named Inventor     | Michael G. Orchard     |
|  |   |    |   | Art Unit                 | 1614                   |
|  |   |    |   | Examiner Name            | Not Yet Assigned       |
| Sheet  | 3 | of | 3 | Attorney Docket Number   | A0345.0021             |

|  |     |   |  |
|--|-----|---|--|
|  |     | extrahepatic tissues by endotoxin," J. Lipid. Res. (2001), 42(3), pp. 452-459   |  |
|  | CG1 | OVERKLEEF, H.S. ET AL., "Generation of Specific Deoxynojirimycin-type Inhibitors of the Non-lysosomal Glucosylceramidase," J. Biol. Chem. (1998), 273, pp. 26522-26527                          |  |
|  | CH1 | FRANCES M. PLATT ET AL., "N-Butyldeoxygalactonojirimycin Inhibits Glycolipid Biosynthesis but Does Not Affect N-Linked Oligosaccharide Processing," J. Biol. Chem. (1994), 269, pp. 27108-27114 |  |
|  | CI1 | RAO, V.S. ET AL., "Regioselective eliminations in reactions of carbohydrate derivatives with superoxide, or with borohydride in 2-propanol," Can. J. Chem. (1981), 59(2), pp. 333-338           |  |
|  | CJ1 | RYAN, J.L. ET AL., "Changes in Membrane Gangliosides: Differentiation of Human and Murine Monocytic Cells," Yale J. Biol. Med. (1985), 58(2), pp. 125-131                                       |  |
|  | CK1 | J.S. SCHNEIDER, "GM1 Ganglioside in the Treatment of Parkinson's Disease," Anatomy and Cell Biology, (1990), 845, pp. 363-373   |  |
|  | CL1 | KATSUHIKO YANAGISAWA ET AL., "GM1 ganglioside-bound amyloid $\beta$ -protein ( $A\beta$ ): A possible form of preamyloid in Alzheimer's disease," Nat. Med. (1995), 1, pp. 1062-1066            |  |
|  | CM1 | HERBERT C. YOHE, ET AL., "Ganglioside alterations in stimulated murine macrophages," Biochim. Biophys. Acta (1985), 818(1), pp. 81-86   |  |
|  | CN1 | HERBERT C. YOHE, ET AL., "Ganglioside expression in Macrophages from Endotoxin Responder and Non-Responder Mice," Immunol. (1986), 137(12), pp. 3921-3927                                       |  |
|  | CO1 | HERBERT C. YOHE ET AL., "The Presence of Sialidase-Sensitive Sialosylgangliosyl Ceramide (GM1b) in Stimulated Murine Macrophages," Immunol. (1991), 146(6), pp. 1900-1908                       |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|